Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2027

Conditions
Colorectal Cancer
Interventions
DRUG

combination therapy Combination: Fruquintinib plus Camrelizumab and HAIC (TOMOX/TOMIRI) Maintenance: Fruquintinib plus Camrelizumab

"Procedure/Surgery: HAIC After successful percutaneous hepatic artery cannulation, superior mesenteric arteriogram and hepatic arteriogram were performed, and after confirming that the subjects were eligible for enrollment according to the results, the hepatic artery was cannulated to the predetermined position. The catheter was connected to a syringe pump in the ward for continuous pumping of drugs.~TOMOX(Raltitrexed 2 mg/m2, Oxaliplatin 85mg/m2)/ TOMIRI(Raltitrexed 2 mg/m2 ,Irinotecan 120mg/m2) Drug: Fruquintinib 3mg, qd, po, 21 days for a cycle, Suspend medication on the day of HAIC Drug: Camrelizumab 200mg, ivgtt,, 21 days for a cycle"

Trial Locations (1)

200062

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT06423937 - Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer | Biotech Hunter | Biotech Hunter